SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001140361-23-050569
Filing Date
2023-10-31
Accepted
2023-10-31 21:56:40
Documents
1
Period of Report
2023-10-27

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 8040
  Complete submission text file 0001140361-23-050569.txt   10253
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 250 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 250 SAN DIEGO CA 92130 650-266-8674
GYRE THERAPEUTICS, INC. (Issuer) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address NIHONBASHI-HONCHO YS BLDG 3F 2-2-2 NIHONBASHI-HONCHO, CHUO-KU TOKYO M0 103-0023
Business Address NIHONBASHI-HONCHO YS BLDG 3F 2-2-2 NIHONBASHI-HONCHO, CHUO-KU TOKYO M0 103-0023 81-3-6214-3600
GNI Group Ltd. (Reporting) CIK: 0001958461 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-51173 | Film No.: 231366365

Mailing Address 12730 HIGH BLUFF DRIVE SUITE 250 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE SUITE 250 SAN DIEGO CA 92130 858-284-0324
GNI USA, Inc. (Reporting) CIK: 0001973229 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-51173 | Film No.: 231366364